股骨头坏死临床药物防治专家共识(2022年)

随着对股骨头缺血性坏死（osteonecrosis of the femoral head,ONFH）认识的深入,且越来越多的患者在疾病早期就诊,ONFH单纯依赖手术治疗已不能满足患者目前的治疗需求,如何合理有效应用药物加强ONFH早期防治,延缓疾病进展越来越重要。本文结合国内外关于符合ONFH中西医诊治原则的最新专家共识和循证医学证据,及国内实际临床应用经验,由中国微循环学会骨微循环专业委员会组织专家撰写本共识,重点介绍ONFH药物的种类、特性、安全性,以及用药的合理性和基本原则,以期为各级医疗机构安全、合理、规范、有效用药提供参考意见。本共识仅为基于文献及临床经验的专家指导性意见,不作为强制性执行的要求,更不作为法律依据。临床中可以根据当地的实际条件因地制宜,制定适合患者的个体化防治措施。

Expert consensus on clinical drug prevention and treatment of osteonecrosis of the femoral head(2022)

With the in-depth understanding of osteonecrosis of femoral head (ONFH),and more and more patients seeking medical treatment in the early stage of the disease,surgical treatment of femoral head necrosis alone is no longer sufficient for the current treatment of patients'' demand,how to rationally and effectively apply drugs to strengthen the early prevention and treatment of femoral head necrosis and delay the progression of disease is becoming more and more important. This article combines the latest expert consensus and evidence-based medical evidence on the principles of ONFH diagnosis and treatment in Chinese and Western medicine at home and abroad,combined with domestic actual clinical application experience,and is organized by experts from Association Related to Circulation Osseous Chinese Microcirculation Society (CSM-ARCO) to write this consensus,focusing on the types of ONFH drugs,the characteristics,safety,rationality and basic principles of drug use provide reference opinions for the safe,reasonable,standardized and effective drug use of medical institutions at all levels. This consensus is only an expert guideline based on literature and clinical experience,not as a requirement for mandatory implementation,let alone as a legal basis. The clinical practice could be tailored to the actual local conditions to develop appropriate prevention and treatment measures for patients.